

#13
5/21/03
mp**Request
For
Continued Examination (RCE)
Transmittal**Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/985,974
Filing Date	November 7, 2001
First Named Inventor	Jorge D. Brioni
Art Unit	1617
Examiner Name	Bahar, Mojdeh
Attorney Docket Number	6753.US.02

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114a. ☐ Previously submittedi. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).ii. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____iii. ☐ Other _____b. ☒ Enclosedi. ☒ Amendment/Replyiii. ☐ Information Disclosure Statement (IDS)ii. ☐ Affidavit(s)/ Declaration(s)iv. ☒ Other Petition to ReviveRECEIVED
MAR 26 2003

OFFICE OF PETITIONS

2. Miscellaneousa. ☒ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of three months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)b. ☐ Other _____**3. Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to

a. ☒ Deposit Account No. 01-002503/25/2003 BNGUYEN1 00000102 010025 09985974i. ☒ RCE fee required under 37 CFR 1.17(e)02 FC:1801750.00 CHii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)03 FC:1253930.00 CHiii. ☒ Other Petition to Revive of an Application for Patent Abandoned Unintentionallyb. ☐ Check in the amount of \$ _____ enclosedc. ☐ Payment by credit card (Form PTO-2038 enclosed)**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.****SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**Name (Print/Type) Michael J. WardRegistration No. (Attorney/Agent) 09985974Signature [Signature]Date 3/18/03**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type) Tanya M. ParentSignature [Signature]Date March 18, 200309985974
03/25/2003
00000102
010025
02 FC:1801
03 FC:1253
Adjustment
03/25/2003
00000102
010025
02 FC:1801
03 FC:1253



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTS

#12
5/21/03
mf

Applicants: Brioni, *et al.*

Serial No.: 09/985,974

Filed: November 7, 2001

Title: THE USE OF SELECTIVE
DOPAMINE BY RECEPTOR AGONISTS
FOR TREATING SEXUAL
DYSFUNCTION

Case No.: 6753.US.02

Group Art No.: 1617

Examiner: Bahar, Mojdeh

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Box RCE
Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: March 18, 2003

Tanya Parent

Date

Box RCE
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 26 2004

RESPONSE

OFFICE OF PETITIONS

Dear Sir:

This communication is responsive to the Office Action dated September 10, 2002 and is accompanied by a Petition To Revive An Unintentionally Abandoned Application under 37 C.F.R. §1.137 (b)(3).

Claims 1-30 are pending.

Claims 1, 5, 15-22, 26, 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 stand rejected.

Applicants reserve the right to file divisional applications on all non-elected subject matter of the instant application.

The Applicants mistakenly elected claims 16 and 39 in the August 8, 2002 Response, where claims 14 and 29 should have been elected.

Claims 1, 5, 22 and 26 (all in part), 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 stand rejected under 35 USC 103(a) as unpatentable over Glase *et al.* and Zorn *et al.* in view of US 5,714,487 to Sanner. Applicants respectfully submit that the cited references do not teach or suggest the use of D4 agonist for treating sexual dysfunction.

Accordingly, Applicants respectfully request allowance of the claims.



ABBOTT LABORATORIES
Telephone: (847) 938-3490
Facsimile: (847) 938-2623

Respectfully submitted,
Brioni, *et al.*

Michael J. Ward
Registration No. 37,960
Attorney for Applicants